Trial Profile
A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥75 Years Old) With Nocturia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Nov 2020
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Adverse reactions; Registrational
- Sponsors Serenity Pharmaceuticals Corporation
- 17 Jul 2012 New trial record